Eli Lilly and Co (LLY) Position Increased by Martingale Asset Management L P

Martingale Asset Management L P lifted its stake in Eli Lilly and Co (NYSE:LLY) by 3.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 559,684 shares of the company’s stock after purchasing an additional 19,614 shares during the period. Eli Lilly and makes up 0.6% of Martingale Asset Management L P’s investment portfolio, making the stock its 25th largest holding. Martingale Asset Management L P owned 0.05% of Eli Lilly and worth $47,272,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in LLY. Gradient Investments LLC acquired a new position in Eli Lilly and during the fourth quarter worth about $103,000. Acrospire Investment Management LLC raised its position in Eli Lilly and by 16.7% during the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after acquiring an additional 200 shares during the last quarter. MPS Loria Financial Planners LLC acquired a new position in Eli Lilly and during the second quarter worth about $128,000. San Francisco Sentry Investment Group CA acquired a new position in Eli Lilly and during the second quarter worth about $129,000. Finally, Front Row Advisors LLC acquired a new position in Eli Lilly and during the fourth quarter worth about $137,000. Hedge funds and other institutional investors own 75.71% of the company’s stock.

In related news, SVP Jeffrey N. Simmons sold 9,625 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $81.12, for a total value of $780,780.00. Following the completion of the sale, the senior vice president now directly owns 152,120 shares in the company, valued at $12,339,974.40. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $81.09, for a total transaction of $72,981.00. Following the completion of the sale, the insider now owns 4,130 shares of the company’s stock, valued at $334,901.70. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 259,610 shares of company stock valued at $22,727,406. 0.20% of the stock is owned by insiders.

A number of equities analysts have issued reports on the stock. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the stock a “sell” rating in a research report on Tuesday, December 5th. Credit Suisse Group restated a “hold” rating and set a $80.00 target price on shares of Eli Lilly and in a research report on Friday, February 2nd. Argus upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and lifted their target price for the stock from $85.52 to $115.00 in a research report on Friday, January 5th. Jefferies Group set a $100.00 target price on shares of Eli Lilly and and gave the stock a “buy” rating in a research report on Tuesday, January 16th. Finally, Bank of America cut their target price on shares of Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating for the company in a research report on Thursday, February 1st. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $93.22.

Shares of Eli Lilly and Co (NYSE:LLY) opened at $77.55 on Thursday. Eli Lilly and Co has a twelve month low of $73.69 and a twelve month high of $89.09. The company has a market cap of $84,963.62, a PE ratio of -387.73, a PEG ratio of 1.45 and a beta of 0.23. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66.

Eli Lilly and (NYSE:LLY) last released its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 31.44%. The firm had revenue of $6.16 billion during the quarter, compared to the consensus estimate of $5.93 billion. During the same period in the previous year, the firm earned $0.95 earnings per share. Eli Lilly and’s revenue was up 7.0% compared to the same quarter last year. research analysts predict that Eli Lilly and Co will post 4.87 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be issued a $0.5625 dividend. This represents a $2.25 dividend on an annualized basis and a yield of 2.90%. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s payout ratio is presently -1,124.94%.

COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/22/eli-lilly-and-co-lly-position-increased-by-martingale-asset-management-l-p.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply